Effects of Vitamin D2 Supplementation on Vitamin D3 Metabolism in Health and CKD

Background and objectives Vitamin D supplements are prescribed to correct low circulating concentrations of 25-hydroxyvitamin D. In CKD, vitamin D metabolism is complicated by decreased conversion of 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D by CYP27B1 and possibly decreased conversion of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D by CYP24A1. The aim of this study was to determine the effects of vitamin D 2 supplementation on vitamin D metabolism in health and CKD. Design, setting, participants, & measurements We conducted a treatment-only intervention study of 25 individuals with CKD (eGFR<60 ml/min per 1.73 m 2 ) and 44 individuals without CKD from three academic centers, all with screening 25-hydroxyvitamin D <30 ng/ml. Each participant was prescribed vitamin D 2 (ergocalciferol) 50,000 IU orally twice weekly for 5 weeks. We tested whether changes in plasma concentrations of vitamin D metabolites and vitamin D metabolic ratios differed by CKD status. Plasma 1,25-dihydroxyvitamin D 3 -to-25-hydroxyvitamin D 3 ratio and 24,25-dihydroxyvitamin D 3 -to-25-hydroxyvitamin D 3 ratio were calculated as estimates of CYP27B1 and CYP24A1 function, respectively. Results With treatment, plasma 25-hydroxyvitamin D 2 and total 25-hydroxyvitamin D concentrations increased similarly for participants with and without CKD. For participants without CKD, 1,25-dihydroxyvitamin D 2 increased (2.8±1.3–32.9±1.4 pg/ml), whereas 1,25-dihydroxyvitamin D 3 decreased (45.6±1.9–14.6±1.9 pg/ml), resulting in no significant change in total 1,25-dihydroxyvitamin D; 1,25-dihydroxyvitamin D 3 -to-25-hydroxyvitamin D 3 ratio decreased (3.0±0.2–1.7±0.2 pg/ng), and 24,25-dihydroxyvitamin D 3 -to-25-hydroxyvitamin D 3 ratio increased (115.7±7.8–195.2±7.9 pg/ng). Individuals with CKD had lower baseline levels and smaller changes in magnitude for 1,25-dihydroxyvitamin D 2 (2.1±1.6–24.4±1.6 pg/ml; P interaction =0.01), 1,25-dihydroxyvitamin D 3 -to-25-hydroxyvitamin D 3 ratio (1.8±0.2–1.1±0.2 pg/ng; P interaction =0.05), and 24,25-dihydroxyvitamin D 3 -to-25-hydroxyvitamin D 3 ratio (72.0±9.1–110.3±9.3 pg/ng; P interaction <0.001). Fibroblast growth factor-23 and parathyroid hormone were not significantly changed in either group. Conclusions Vitamin D 2 supplementation decreases conversion of 25-hydroxyvitamin D 3 to 1,25-dihydroxyvitamin D 3 and induces vitamin D 3 catabolism as evidenced by changes in D 3 metabolites and vitamin D metabolic ratios. These effects occur without significant changes in fibroblast growth factor-23 or parathyroid hormone and are blunted in CKD. Podcast This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2017_08_02_CJASNPodcast_17_09.mp3